#### RECEIVED CENTRAL FAX CENTER

APR 0 2 2004

## WEBB ZIESENHEIM LOGSDON ORKIN & HANSON, P.C.

### FACSIMILE INFORMATION SHEET

WEBB Z	IESENHEIM LOGSDON ORKIN & HANSON, P.C. 700 Koppers Building 436 Seventh Avenue	OFFICIAI
Tele	Pittsburgh, PA 15219-1818 phone: 412-471-8815 Facsimile: 412-471-4094 E-mail: webblaw@webblaw.com	APK 0 6 2004 
	FACSIMILE INFORMATION SHEET	104 OF 1004
Name of Individual:		- 1600/22
Company:	United States Patent and Trademark Office	
City and State:	Alexandria, VA 22313	<del></del>
Facsimile Number:	703-872-9306	
From:	Gwen R. Wood, Ph.D.	
Total Number of Pages:	7	
Date Transmitted:	April 2, 2004	·
	Client No.: 702 File No.: 010802	<del></del>
Message: Please find	attached the following for filing in the above-referenced file:	
Supplemen Transmittal	tal Amendment (U.S. Patent No. 09/856,277) and Amendment Letter	·
If you do not recei	ve all pages, please call back as soon as possible. The number is (41)	2) 471-

CERTIFICATE OF FACSIMILE TRANS	MISSION
VIA FACSIMILE NO.: 703-872-9306  I hereby certify that this paper is being facsimile t United States Patent and Trademark Office on the da	
Helen Gerace	
(Typed Name of Person Signing Certific	ation)

{W0114184.1}

8815.

STATEMENT OF CONFIDENTIALITY

The information in this facsimile is privileged and confidential and is intended only for the use of the named recipient. Disclosure or copying of this document or its contents other than by the named recipient is prohibited. If this document is received in error, it should be returned to sender. If there are any reception problems, please call 412-471-

Attorney's Docket No. 702-010802

AMENDMENT TR	APR 0 6 2004
	APR
Fax No.: 703-872-9306	
Commissioner for Patents	1204 Cr. 1 2004
P.O. Box 1450	· CANTED
Alexandria, VA 22313-1450	Filing Date: August 20, 2001
	7291J
Application No.: 09/856,277	1 11118 3 4 4 4 4
Examiner: Sharmila S. Gollamudi	Group Art Unit: 1616
Invention: Oral Creatine Supplementation for I	reating or Preventing Muscle Disuse Syndrome
Transmitted herewith is a Supplemental Amendme	nt in the above-identified application.
Small entity status of this application	on under 37 CFR 1.27 has been established by a
verified statement previously submi	ited.
A verified statement to establish small	ll entity status under 37 CFR 1.9 and 1.27 is enclosed.
<ul><li>X</li><li>X</li><li>X</li><li>X</li><li>Do additional fee is required.</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><li>X</li><l></l></ul>	- holony
X The fee has been calculated as show	n below.
No. of Claims Highest No.	
after Previously Present	Small Entity Non-Small
Amendment Paid For Extra	Rate Entity Rate Charge
Total 8 20 -0 x	\$ 9.00 \$ 18.00 \$ -0-
Indep. 2 3 -0- x	\$ 43.00   \$ 86.00   \$ <u>-0-</u>
	+ \$145.00 + \$290.00 \$0-
First Presentation of Multiple Dependent Claims	TOTAL ADDITIONAL FEE \$ -0-
	OTAL ADDITIONALTEE U
associated with this communication	norized to charge payment of the following fees to Deposit Account No. 23-0650. Please refund any p. 23-0650. An original and two copies of this sheet
X Any additional filing fees required t	inder 37 CFR 1 16
X Any patent application processing for	
	92120
April 2, 2004	By foul 1/1/1
Date	Gwen R. Wood, Ph.D.
The book of the bo	Registration No. 51,027
I hereby certify that this paper is being facsimile transmitted to the United States Patent and Trademark Office on April 2, 2004	Attorney for Applicant
Holon Garage	436 Koppers Building
Helen Gerace (Name of Person Mailing Paper)	436 Seventh Avenue
Hel Sera April 2, 2004	Pittsburgh, PA 15219-1818
Signature Date	Telephone: (412) 471-8815
	Facsimile: (412) 471-4094
	E-mail: webblaw@webblaw.com

Further response to Office Action of August 19, 2003

APR 0 6 2004 ECH CENTER 1600/2900

RECEIVED CENTRAL FAX CENTER

APR 0 2 2004

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

Application No. 09/856,277

Attorney Docket No. 702-010802

Paper dated April 2, 2004

09/856,277

Applicant

Peter Jozef Leo Hespel

Filed

August 20, 2001

Title

Oral Creatine Supplementation for Treating or Preventing

Muscle Disuse Syndrome

Group Art Unit

1616

Examiner

Sharmila S. Gollamudi

Confirmation No.

6608

Customer No.

28289

FACSIMILE NO.: 703-872-9306

Commissioner of Patents P.O. Box 1450

Alexandria, VA 22313-1450

#### SUPPLEMENTAL AMENDMENT

Sir:

In further response to the Office Action of August 19, 2003, please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 4 of this paper.

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on April 2, 2004.

Helen Gerace
(Name of Person Mailing Paper)

Helen Gerace
The Correct of Person Mailing Paper)

Helen Gerace Date

1

{W0113691.1}